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Objectives: The benefits of resection for metachronous lung cancer are not well
described. The objective of this study was to evaluate the safety and efficacy of
surgical resection for metachronous lung cancers.
Methods: We reviewed the charts of all patients who underwent a second resection
for a metachronous lung cancer from July 1, 1988, to December 31, 2002. Type of
resection, operative morbidity, mortality, and survival by stage were analyzed.
Survival was determined by using the Kaplan-Meier survival method. All patients
were pathologically staged by using the 1997 American Joint Committee on Cancer
standards.
Results: Pulmonary resections were performed in 69 patients who had undergone a
previous resection. The mean interval between the first and second resection was 2.4
 2.5 years. Seventy-three percent of patients presented with stage I cancers, 9%
with stage II cancers, and 17% with stage III cancers. Lobectomy and wedge
resection were performed with equal frequency (42% each) for the metachronous
cancers. Operative mortality for the second resection was 5.8%. The mean follow-up
after the second resection was 37 months. Overall 5-year actuarial survival for the
entire group after the second resection was 33.4%.
Conclusions: Operations for metachronous cancers provided survival that approxi-
mated the expected survival for lung cancer. Surgical intervention should be
considered as a safe and effective treatment for resectable metachronous lung cancer
in patients with adequate physiologic pulmonary reserve.
Approximately 50% of the 170,000 patients with newly diagnosedlung cancer will have localized disease that is amenable to po-tentially curative therapy.1,2 Patients with stage I and stage IInon–small cell lung cancers (NSCLCs) who undergo completesurgical resection have a favorable prognosis, with actuarial5-year survivals that range from 55% to 75% and 35% to 45%,
respectively.1,3-5 Factors that limit long-term survival include the patients’ under-
lying comorbidity,6 tumor recurrence, and the development of second primary lung
cancers.7-9 Although there has been considerable debate concerning the usefulness
of postoperative surveillance in decreasing the mortality associated with recurrent
NSCLC,10-14 early identification and surgical resection of second primary lung
cancers has been associated with encouraging results.15-22
The risk of development of a new primary lung cancer after undergoing
definitive surgical therapy for an NSCLC is estimated to be 1% to 2% per patient
per year.8,9 However, differentiating synchronous primary lung cancers from
intrapulmonary metastases and metachronous lung cancers from recurrent lung
cancer can be difficult when the tumor histology is the same. According to the
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guidelines proposed by Martini and Melamed,23 tumors
with the same histology might be considered synchro-
nous if they are found in a different segment, lobe, or
lung; there is no carcinoma in lymphatics common to
both; and there is no evidence of extrapulmonary metas-
tasis at the time of diagnosis. Tumors with the same
histology might be considered metachronous if there has
been a disease-free interval between cancers of at least 2
years or the second tumor is found in a different segment,
lobe, or lung; there is no carcinoma in the lymphatics
common to both; and there is no evidence of extrapul-
monary metastasis at the time of diagnosis. Although
these guidelines remain useful, the routine use of spiral
computed tomographic (CT) imaging in the preoperative
staging and postoperative surveillance of patients with
NSCLCs has been responsible for the identification of
many additional small cancers.
Because accurate differentiation of synchronous or meta-
chronous tumors from intrapulmonary metastases or recur-
rent lung cancer is not always clinically possible, patients
with adequate pulmonary and physiologic reserve have un-
dergone surgical resection of these second lesions. The
purpose of this study was to determine the effect of com-
pletely resected metachronous NSCLC on survival.
Methods
Population Under Study
A database analysis of our cardiothoracic surgery tumor registry
was performed. From July 1, 1988, to December 31, 2002, a
total of 2107 patients underwent pulmonary resection for
NSCLC. During this period, 69 patients underwent multiple
resections for NSCLC. The surgical pathology reports of all
patients who underwent multiple resections identified by this
database query were individually reviewed, and the final patho-
logic staging was assigned by using the 1997 revisions in the
International System for Staging Lung Cancer. Patients who
underwent anatomic resection of an NSCLC who had previ-
ously undergone excision by means of wedge excision in the
same lobe were excluded from this analysis.
Tumor recurrence, patient survival, and cause of death were
determined for each patient. Follow-up information on all patients
was acquired within the last 6 months through clinic follow-up
notes, direct patient or family contact, contact with the patient’s
primary care physician, and review of all death certificates. This
study represents a secondary data analysis of a prospective cohort
study. Approval for this study was granted by the Washington
University School of Medicine Human Studies Committee.
Statistical Analysis
Descriptive statistics were used to describe the patients’ charac-
teristics and outcomes. Normally distributed continuous data are
expressed as means  SD throughout. Medians with ranges are
used when continuous data are not normally distributed. Categoric
data are expressed as counts and proportions. Fisher exact or 2
tests were used to analyze the categoric data.
Kaplan-Meier (product-limit) graphs were used to demonstrate
survival over time and freedom from recurrence of disease. Sur-
vival comparison between groups of patients was completed by
using the Mantel-Haenszel log rank test.
All data analysis was performed with Systat software (Systat
10.0 for Windows; SPSS Inc, Chicago, Ill).
Results
Patient Demographics
Of the 69 patients in this experience, 36 (52%) were male
and 33 (48%) were female. The mean ages at the time of the
first and second resections were 65.1  8.7 and 67.5  8.9
years, respectively. The majority of patients had stage I
disease at the time of both the first (44/69 [64%]) and
second (50/69 [73%]) resections (Table 1). However, the
remaining 25 patients were found to have more advanced
disease at the time of the first resection because of lymph
node metastases (n  16), chest wall invasion (n  5), or
multifocal lung cancer (n  4). At the time of the second
resection, 19 patients were found to have more advanced-
stage disease because of lymph node metastases (n  7),
chest wall invasion (n  3), or multifocal lung cancer (n 
9).
Pulmonary function test results were available for review
on 43 of 69 patients before the initial resection and on 45 of
69 patients before the second resection (Table 2). The mean
forced expiratory volume in 1 second (percent predicted)
before the first and second resections for this group of
patients was 81% and 65%, respectively. The mean arterial
blood gas PaO2 and PaCO2 values were also in the normal
range for this group before the first and second resections.
Sixty-one (88%) patients underwent anatomic resection
of their lung cancer at the time of the first resection (Table
3). The majority underwent lobectomy (78%). However, 6
(9%) patients required a more extensive operation to ensure
complete resection. Nine patients with small lesions under-
went limited pulmonary resection by means of segmentec-
tomy (1%) or wedge excision (12%). Surgical resection of
the metachronous NSCLC was accomplished with anatomic
resection in 40 (58%) patients. Twenty-nine (42%) patients
underwent lobectomy, 2 (3%) patients underwent bilobec-
tomy, and 4 (6%) patients underwent completion pneumo-





Stage IA 30 (43.5%) 34 (49.3%)
Stage IB 14 (20.3%) 16 (23.2%)
Stage IIA 5 (7.2%) 3 (4.3%)
Stage IIB 11 (15.9%) 3 (4.3%)
Stage IIIA 5 (7.2%) 4 (5.8%)
Stage IIIB 3 (4.3%) 8 (11.6%)
Stage IV 1 (1.4%) 1 (1.4%)
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nectomy. Thirty-four (49%) patients with small peripheral
lesions underwent limited pulmonary resection by means of
segmentectomy (7%) or wedge excision (42%) to preserve
pulmonary function.
The metachronous lung cancer was in the contralateral
lung in 52 (75%) patients and the ipsilateral lung in 17
(25%) patients. Forty-three (62%) patients had tumors with
the same histology, and 26 (38%) had tumors with different
histology (Table 4). Adenocarcinoma was the most fre-
quently identified histologic subtype encountered: 40 (58%)
patients had a least one tumor that was an adenocarcinoma.
Only 3 patients had bronchioloalveolar cancer identified in
both lesions, and 3 patients had bronchioloalveolar cancer
in addition to adenocarcinoma (n  1) or squamous cell
cancer (n 2). Forty (58%) patients underwent resection of
their metachronous lung cancer within 2 years of the initial
resection.
Survival
Survival data were collected on each patient from the dates
of the operation. There were 4 (5.8%) postoperative deaths
after resection of the metachronous NSCLC in this series.
All 4 deaths were caused by respiratory failure associated
with pneumonia. The 5-year actuarial survival for all pa-
tients after resection of metachronous NSCLC was 60.9%
and 33.4% after resection of the primary and metachronous
lesions, respectively. The 5-year actuarial survival of pa-
tients who had stage I NSCLC at the time of the first
resection was not significantly different than that of patients
who had more advanced tumors initially resected (73% vs
39%, P  .07; Figure 1). However, the 5-year actuarial
survival of patients who had metachronous stage I NSCLC
resected was significantly better than that in patients with
more advanced metachronous lesions (42% vs 10%, P 
.01; Figure 2).
Effect of Tumor Histology and Interval Between
Resections on Survival in Patients With Metachronous
NSCLC
To determine whether specific subgroups of metachronous
NSCLC had a more favorable prognosis, we examined
survival in patients with multiple tumors with the same
histology (which would include patients with intrapulmo-
nary metastases) and those with different histology. There
was no difference in survival between these groups (Figure
3). Because many investigators exclude patients with a short
disease-free interval between resection of metachronous
lesions, we examined survival in patients in whom the
interval between resection of their metachronous lung can-
cers was less than 24 months and in those in whom the
interval was greater than 24 months. There was no differ-
ence in survival between these groups (Figure 4).
Discussion
Patients successfully treated for their initial NSCLC have a
risk of having a second NSCLC of approximately 1% to 2%
per patient per year. Optimal management of metachronous
lung cancer is affected by a number of factors, including the
patient’s pulmonary reserve, associated medical comorbid-
ity, and the clinical stage of the second lung cancer. The 69
patients in this series who underwent resection of their
metachronous lung cancer represented approximately 3% of
all patients who underwent surgical intervention for NSCLC
during this 14-year period at our institution and is similar to
the incidence of metachronous lung cancer reported by
other investigators.16,19,20 All of these series (including our
own) likely underestimate the true incidence of metachro-
nous lung cancer because only patients with the physiologic
reserve to undergo a second resection are included.
Patients who underwent resection of metachronous lung
cancer had overall 5-year survivals of 61% and 33% after





FEV1 (% predicted) 81.1 23 65.2 17
FVC (% predicted) 96.2 23 86.4 19
PO2 (mm Hg) 78 10 80 9
PCO2 (mm Hg) 39 8 37 4
FEV1, Forced expiratory volume in 1 second; FVC, forced vital capacity.





Lobectomy 54 (78.3%) 29 (42.0%)
Bilobectomy 3 (4.3%) 2 (2.9%)
Segmentectomy 1 (1.4%) 5 (7.2%)
Pneumonectomy 3 (4.3%) 4 (5.9%)
Wedge(s) 8 (11.7%) 29 (42.0%)








Adenocarcinoma  squamous 14
Adenocarcinoma  mixed 5
Adenocarcinoma  neuroendocrine 1
Squamous  other 2
Adenocarcinoma  BAC 2
Squamous  BAC 1
Neuroendocrine  other 1
BAC, Bronchioloalveolar cancer.
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resection of their initial and metachronous lung cancers,
respectively. There are many factors that likely contribute to
the favorable survival observed in patients who underwent
resection of their metachronous lung cancers in this analy-
sis. Patients selected for resection had adequate physiologic
reserve, as evidenced by a relatively low operative mortality
(5.8%). The final pathologic stage of the metachronous
tumor was stage I in 73% of the patients. Finally, the
majority (58%) of these patients underwent anatomic resec-
tion of their second NSCLC by means of segmentectomy,
lobectomy, bilobectomy, or completion pneumonectomy.
In this analysis we did not attempt to differentiate in-
trapulmonary metastases from second primary lung cancers.
However, there was no difference in survival between pa-
tients with multiple tumors of the same histology (which
would include patients with intrapulmonary metastases) and
patients with tumors of different histology. Similarly, there
was no difference in survival among patients who under-
Figure 1. Five-year actuarial survival from the time of the first resection of the entire group stratified by the stage
of the primary NSCLC.
Figure 2. Five-year actuarial survival from the time of the second resection of the entire group stratified by the
stage of the metachronous NSCLC.
Figure 3. Five-year actuarial survival from the time of the second resection of the entire group stratified by tumor
histology.
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went resection of a metachronous lesion within 2 years and
those patients whose interval between resections was
greater than 2 years. Although molecular techniques have
been developed to compare tumors of the same histology in
an attempt to differentiate intrapulmonary metastases from
metachronous lung cancers,24,25 these techniques were not
used in this series and are of no value in the preresection
analysis of tumor cytology.
All of these patients were carefully staged by means of
CT imaging of the chest and upper abdomen to include the
liver and adrenal glands. In addition, extrathoracic metas-
tases were excluded by using CT or magnetic resonance
imaging of the brain and nuclear bone scans. More recently,
positron emission tomography imaging has been used to
exclude distant metastatic spread.
The management of patients in whom a second primary
lung cancer develops remains a challenging problem. How-
ever, there is a small but real group of patients who appear
to benefit from surgical resection of their second NSCLC.
Therefore we believe that the algorithm used to evaluate
these patients for surgical resection of the second lesion
should be identical to that used at the time of the first
resection, and we continue to recommend complete surgical
resection of metachronous NSCLC in patients with ade-
quate physiologic reserve.
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Discussion
Dr Richard I. Whyte (Stanford, Calif). First, I would like to
congratulate Dr Battafarano on a very interesting article and one
that certainly adds to our body of knowledge about metachronous
lung cancers.
I have 2 comments and 3 questions. My first comment gets to
the purpose of the study, which you described here as to determine
the effect of surgical intervention on metachronous lung cancers.
In your article, however, I think you described the purpose as
being to determine the effect of completely resected metachronous
lung tumors on survival. Therefore in one sense it is comparing
whether surgical intervention makes a difference, which is hard to
answer if you have no patients who did not have an operation,
whereas you can compare the survival of those who had metachro-
nous tumors with those who did not in your current study.
The other question gets to the conclusion that this should be
done on all patients with metachronous tumors, and what I noticed
in reviewing the data is that the patients who had stage I disease
from their primary tumor had a 5-year survival of 75% versus
down to 42% in the metachronous patients. Therefore it is sub-
stantially lower, perhaps not significantly, but I think substantially
lower, whereas in those patients who had more advanced-stage
disease, the 5-year survival was only 10%. And you had a 6%
mortality. I am not sure that your 10% survival even accounts for
that 6% mortality. Therefore those patients do what appears to be
extremely poorly, and it certainly at least makes one address the
issue that these patients should be very thoroughly staged before
offering them an operation. My questions are 3-fold. First, given a
1% to 2% incidence of new cancers, you are reporting on 3% of
your 2100 patients over the time period, and my question is what
happened to the rest of the cancers?
Dr Battafarano. This is a selected group of patients, and even
in the patients who had more advanced disease, most of this was
found at the time of the operation. As you know, our group
routinely uses mediastinoscopy, and therefore any patients with a
positive mediastinoscopy-biopsy result would be excluded. That is
why there is such a propensity for patients with stage I disease in
this group. But what happened to the other patients? Many of those
patients were excluded because at the time of our staging evalua-
tion, they were found to have more advanced disease or such
advanced disease that they would not tolerate the pulmonary
resection necessary to enjoy complete resection on the basis of
their pulmonary function. For instance, they would need a com-
pletion pneumonectomy, and their pulmonary function would not
allow. I do not have the exact denominator. However, the percent-
age of our patients who underwent a second resection was about
3% of the total volume of patients who underwent pulmonary
resection for lung cancer during that period. Others who have
reported on their metachronous experience have proportions that
have been more in the 4% range, and one article had results as high
as 5%. Therefore I think our selection might have been even a little
bit more rigorous or we had a patient population whose pulmonary
function would not have allowed complete resection of their dis-
ease at the time of metachronous resection.
Dr Whyte. On the basis of 1% to 2% per year, you would think
in that follow-up period that you would get more than a total of 3%
of your overall cases. That kind of gets to the second question.
Where were these patients followed after their original operation?
Were they followed by the division of cardiothoracic surgery, the
section of thoracic surgery, or were they sent elsewhere and to
come back if they had a new primary? And what happened in the
interim? Were they followed with chest radiography or CT scans?
How often? What was the frequency of that type of follow-up?
That will help determine how many new patients with cancer you
see.
Dr Battafarano. We follow all of our patients postoperatively.
They are seen every 4 months for the first 3 years and then every
6 months thereafter. They are seen initially with chest radiography.
If they have any abnormality on their chest X-ray films, we will
perform a CT scan. Therefore we do follow them closely, and
those patients in this study were identified by us in our normal
surveillance program. But you are right, it is a small but real group
that we identify who are able to withstand a second resection.
Dr Whyte. The last question concerns the fact that the pulmo-
nary function test results were fairly similar, and you did not, in
your article, say whether they were statistically significantly dif-
ferent. There was some slight decrease in forced expiratory volume
in 1 second in the persons undergoing a second operation, but they
were not all that different, yet 42%, or nearly half, had wedge
resections. I think most of us think that is not the best operation for
lung cancer. I was wondering how you decided which patients
would get lobectomies and which patients would get wedge resec-
tions.
Dr Battafarano. Well, I think it is individual. As you know,
with every retrospective series, you cannot identify each of those
things. I think the first thing is that all of the people in this series
had negative margins on their permanent section. Therefore I think
that if it was the surgeon’s decision that they could perform a wide
wedge excision on the lesion and wanted to preserve function that
was a decision made by the surgeon. You can see from the series,
though, that 29 underwent wedges, but most of them still under-
went lobectomy or more. Therefore the idea of taking those pa-
tients to the operating room is to get a complete resection. But I
think for the smaller lesions, the T1 lesions that were peripheral,
that was the individual surgeon’s decision to make on the basis of
their pulmonary function tests and the location of the lesions
whether a wedge resection was performed.
Dr Whyte. But given your choice, you prefer a lobe, I take it?
Dr Battafarano. Yes, for sure. We are very aggressive in
performing anatomic resections on all NSCLCs.
Dr Scott J. Swanson (New York, NY). You mentioned medi-
astinoscopy a minute ago. Can you tell me what percentage of your
patients initially had mediastinoscopy, and then how you did your
preresectional mediastinal evaluation the second time around?
Dr Battafarano. Well, it varied partly because of the time
sequence. If a person had a mediastinoscopy performed previ-
ously, then unless there were target lymph nodes or something,
then a mediastinoscopy was not routinely done. In the first group
of patients, a mediastinoscopy was performed in all 69 patients
before their first resection. Again, there might have been persons in
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the series who had a large target lesion and not in the series of 69
but during the process of following our patients. If they had a
target lesion on CT or other imaging, we will perform repeat
mediastinoscopy.
Dr Swanson. How many had a repeat mediastinoscopy?
Dr Battafarano. I think it was only 15.
Dr Swanson. And if mediastinal sampling is important the first
time around and you performed it for all patients, is it not equally
important the second time around, and should you not do some
evaluation, endoscopic ultrasonography with fine-needle aspira-
tion, or thoracoscopic sampling to get at that same information?
Dr Battafarano. Well, on the basis of the series there, and you
can see it by the second resection, it was very much bent toward
stage I lesions. What happened was that all those patients then had
mediastinal lymph nodes biopsied at the time of the operation.
Dr Swanson. Through a thoracotomy?
Dr Battafarano. Exactly.
Dr Daniel L. Miller (Atlanta, Ga). Did you look to see whether
there was any difference in how the patient presented for a second
resection, if it was found on incidental screening within your
follow-up clinic or if it was in regard to symptoms? I think that is
very important because when we looked at our resection after
pneumonectomy while at the Mayo Clinic, we found that it made
a tremendous difference in survival if they presented with symp-
toms compared with when they are found incidentally on screen-
ing.
Dr Battafarano. The large majority of these patients were
asymptomatic at the time of diagnosis. But again, being retrospec-
tive, I think now many more of our more recent patients are getting
CTs, either by us in the follow-up clinic because of an abnormal
chest X-ray film or they will come from an outside physician with
a CT, possibly even performed for another reason if they have had
another malignancy. But the large majority of these patients were
asymptomatic.
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